Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow RECURSION PHARMACEUTICALS, INC.

Get SEC filing alerts via email and in your feed for RECURSION PHARMACEUTICALS, INC.

RXRX

RECURSION PHARMACEUTICALS, INC.

About RECURSION PHARMACEUTICALS, INC.

Recursion Pharmaceuticals is a clinical-stage TechBio company that uses AI, automation, and vast biological and chemical datasets to discover and develop new medicines. Its platform integrates high-throughput wet labs with advanced computational models to accelerate drug discovery, focusing on oncology, rare diseases, and unmet medical needs. Collaborating with major pharma partners, Recursion aims to transform medicine development and improve patient outcomes through innovative, data-driven approaches.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from RECURSION PHARMACEUTICALS, INC.

1
1
RECURSION PHARMACEUTICALS, INC. Recursion Pharmaceuticals Reports 56% Revenue Decline and $117.5 Million Net Loss in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
RECURSION PHARMACEUTICALS, INC. Recursion Pharmaceuticals Reports $644.8 Million Net Loss and Increased Revenue in Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
RECURSION PHARMACEUTICALS, INC. Recursion Pharmaceuticals Reports 80% Revenue Decline and $162M Net Loss in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
RECURSION PHARMACEUTICALS, INC. Recursion Pharmaceuticals Reports 33% Revenue Growth but Increases Net Loss to $171.9 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
RECURSION PHARMACEUTICALS, INC. Recursion Pharmaceuticals Reports $202.5 Million Net Loss and $14.7 Million Revenue in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
RECURSION PHARMACEUTICALS, INC. Recursion Pharmaceuticals Reports $463.6M Net Loss and $58.8M Revenue in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
RECURSION PHARMACEUTICALS, INC. Recursion Pharmaceuticals Reports 100% Revenue Growth, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments